Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

PROPYLTHIOURACIL

All products: general benefit

Propylthiouracil Tablets · DIN 02523019 · 50mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Propylthiouracil Tablets · DIN 02523019 Manufacturer: Phebra Canada; listing date 2022-12-21 Health Canada: Marketed since 2022-07-21 · brand PROPYLTHIOURACIL TABLETS · ATC H03BA02 PROPYLTHIOURACIL · form Tablet · route Oral · ingredients PROPYLTHIOURACIL 50 MG · company Phebra canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Propylthiouracil Tablets: Formulary list price $0.5000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101209 · Verify on the e-Formulary ↗ (DIN 02523019)

Source record
DIN 02523019: Propylthiouracil Tablets Raw flags: sec3=Y Item: 683600030; group id 807; item number 1984; lccId None; manufacturer id PHB Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $0.5000; ministry $0.5000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02523019 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101209
Shortage status: resolved shortage (ended 2024-02-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02523019
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (68:36 Thyroids) and how they are covered

Matched class: 68:36 Thyroids

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): LEVOTHYROXINE (SODIUM) 68:36 Thyroids

LEVOTHYROXINE (SODIUM)

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (2), General benefit (26) · strengths: 0.137mg, 0.025mg, 0.05mg, 0.075mg, 0.088mg, 0.1mg, 0.112mg, 0.125mg, 0.15mg, 0.175mg, 0.2mg, 0.3mg · Tab

LIOTHYRONINE (SODIUM)

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mcg, 25mcg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:36
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS HALYCIL™ (propylthiouracil tablets) is indicated:  For the medical management of hyperthyroidism.  In conjunction with radioiodine to hasten recovery while awaiting the effects of radiation.  For the control of thyrotoxicosis prior to surgery.  In the management of a thyroid storm in addition to other therapeutic measures. 1.1 Pediatrics Pediatrics (<18 years): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (>65 years): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with no differences in safety or effectiveness. https://pdf.hres.ca/dpd_pm/00063155.PDF PM date: OCT 06, 2021 Source product: HALYCIL; DIN 02521059; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.